JPY 456.0
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.4 Billion JPY | 6.66% |
2022 | 1.31 Billion JPY | 4.31% |
2021 | 1.26 Billion JPY | 9.48% |
2020 | 1.15 Billion JPY | -30.25% |
2019 | 1.65 Billion JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 497 Thousand JPY | -4.79% |
2023 FY | 1.4 Billion JPY | 6.66% |
2023 Q1 | 275.57 Million JPY | -4.79% |
2023 Q4 | 454.07 Million JPY | 27.57% |
2023 Q3 | 355.94 Million JPY | 11.98% |
2023 Q2 | 317.87 Million JPY | 15.35% |
2022 Q3 | 415 Million JPY | 35.2% |
2022 Q4 | 289.44 Million JPY | -30.26% |
2022 FY | 1.31 Billion JPY | 4.31% |
2022 Q2 | 306.95 Million JPY | 0.0% |
2021 FY | 1.26 Billion JPY | 9.48% |
2020 FY | 1.15 Billion JPY | -30.25% |
2019 FY | 1.65 Billion JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
KOHJIN BIO CO LTD | 1.28 Billion JPY | -9.264% |
PRISM BioLab Co.,LTD | 576.81 Million JPY | -143.313% |
GNI Group Ltd. | 9.32 Billion JPY | 84.945% |
Linical Co., Ltd. | 2.7 Billion JPY | 48.12% |
Trans Genic Inc. | 2.15 Billion JPY | 35.02% |
MEDINET Co., Ltd. | 1.49 Billion JPY | 5.881% |
Soiken Holdings Inc. | 3.07 Billion JPY | 54.301% |
Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 24.422% |
AnGes, Inc. | 8.9 Billion JPY | 84.235% |
OncoTherapy Science, Inc. | 943.08 Million JPY | -48.817% |
Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 92.686% |
Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -239.83% |
NanoCarrier Co., Ltd. | 975.37 Million JPY | -43.89% |
Carna Biosciences, Inc. | 2.56 Billion JPY | 45.339% |
CanBas Co., Ltd. | 278 Million JPY | -404.843% |
D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -22.945% |
RaQualia Pharma Inc. | 1.81 Billion JPY | 22.8% |
Chiome Bioscience Inc. | 1.6 Billion JPY | 12.489% |
Kidswell Bio Corporation | 2.37 Billion JPY | 40.883% |
PeptiDream Inc. | 9.68 Billion JPY | 85.512% |
Oncolys BioPharma Inc. | 1.96 Billion JPY | 28.416% |
Ribomic Inc. | 1.1 Billion JPY | -26.931% |
SanBio Company Limited | 4.53 Billion JPY | 69.08% |
Healios K.K. | 3.48 Billion JPY | 59.752% |
BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -21.54% |
Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -5.17% |
StemRIM | 2.07 Billion JPY | 32.396% |
CellSource Co., Ltd. | 1.96 Billion JPY | 28.522% |
FunPep Company Limited | 313.82 Million JPY | -347.218% |
Kringle Pharma, Inc. | 958.01 Million JPY | -46.497% |
Stella Pharma Corporation | 963.98 Million JPY | -45.59% |
TMS Co., Ltd. | 943.25 Million JPY | -48.79% |
Noile-Immune Biotech Inc. | 1.08 Billion JPY | -28.764% |
Cuorips Inc. | 598.11 Million JPY | -134.647% |
K Pharma,Inc. | 543.94 Million JPY | -158.017% |
Takara Bio Inc. | 23.9 Billion JPY | 94.129% |
ReproCELL Incorporated | 1.51 Billion JPY | 7.302% |
PhoenixBio Co., Ltd. | 1.18 Billion JPY | -18.537% |
StemCell Institute Inc. | 1.16 Billion JPY | -20.767% |
Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 7.805% |
CellSeed Inc. | 804.93 Million JPY | -74.358% |